Bacterial temporal dynamics enable optimal design of antibiotic treatment

PLoS Computational Biology

Volumn 11, Issue 4, 2015, Pages

  Meredith, Hannah R ^a   Lopatkin, Allison J ^a   Anderson, Deverick J ^b   You, Lingchong ^a,c  

^a Duke University   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDES; BACTERIA; PATHOGENS;

ANTIBIOTIC TREATMENT; ANTIBIOTIC-RESISTANT BACTERIA; BACTERIAL PATHOGENS; BROAD SPECTRUM; DRUG RESPONSE; EXTENDED SPECTRUM Β-LACTAMASES; GRAM POSITIVE; OPTIMAL DESIGN; TEMPORAL DYNAMICS; Β-LACTAM ANTIBIOTICS;

ANTIBIOTICS;

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; EXTENDED SPECTRUM BETA LACTAMASE; BETA LACTAM; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; DRUG DESIGN; DRUG RESPONSE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MOLECULAR MECHANICS; NONHUMAN; PROTEIN EXPRESSION; BACTERIAL PHENOMENA AND FUNCTIONS; BIOLOGICAL MODEL; CELL SURVIVAL; COMPUTER ASSISTED DRUG THERAPY; COMPUTER SIMULATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES; TIME FACTOR;

BACTERIA (MICROORGANISMS); POSIBACTERIA;

BACTERIAL PHYSIOLOGICAL PHENOMENA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CELL SURVIVAL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMPUTER-ASSISTED; MODELS, BIOLOGICAL; TIME FACTORS;

EID: 84929484427     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004201     Document Type: Article

References (85)

1. Clatworthy AE, Pierson E, Hung DT, (2007) Targeting virulence: a new paradigm for antimicrobial therapy. Nature chemical biology 3: 541–548. 17710100
2. Walsh C, (2003) Where will new antibiotics come from? Nature Reviews Microbiology 1: 65–70. 15040181
3. Gilmore MS, Clewell DB, Ike Y, Shankar N, Kristich CJ, et al. (2014) Enterococcal Infection—Treatment and Antibiotic Resistance.
4. MacGowan A, Macnaughton E, (2013) Antibiotic resistance. Medicine 41: 642–648.
5. Čižman M, Pokorn M, Seme K, Oražem A, Paragi M, (2001) The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. Journal of Antimicrobial Chemotherapy 47: 475–477. 11266425
6. Centers for Disease Control and Prevention (2013) Antibiotic Resistance Threats in the United States, 2013. In: Services USDoHaH, editor.
7. Projan SJ, (2003) Why is big Pharma getting out of antibacterial drug discovery? Current opinion in microbiology 6: 427–430. 14572532
8. Fishman N, (2006) Antimicrobial stewardship. American journal of infection control 34: S55–S63. 16813983
9. Weber JT, Courvalin P, (2005) An emptying quiver: antimicrobial drugs and resistance. Emerg Infect Dis 11: 791–793. 15971372
10. Tanouchi Y, Lee AJ, Meredith H, You L, (2013) Programmed cell death in bacteria and implications for antibiotic therapy. Trends in microbiology 21: 265–270. doi: 10.1016/j.tim.2013.04.001 23684151
11. Fisher JF, Meroueh SO, Mobashery S, (2005) Bacterial resistance to β‐lactam antibiotics: compelling opportunism, compelling opportunity. Chemical reviews 105: 395–424. 15700950
12. Hamad B, (2010) The antibiotics market. Nature Reviews Drug Discovery 9: 675–676. doi: 10.1038/nrd3267 20811374
13. Page MG, (2012) Beta-lactam antibiotics. Antibiotic Discovery and Development: Springer. pp. 79–117.
14. MacLaughlin EJ, Saseen JJ, Malone DC, (2000) Costs of beta-lactam allergies: selection and costs of antibiotics for patients with a reported beta-lactam allergy. Archives of family medicine 9: 722–726. 10927711
15. Holten KB, (2000) Appropriate prescribing of oral beta-lactam antibiotics. American family physician 62.
16. Piccirillo JF, Mager DE, Frisse ME, Brophy RH, Goggin A, (2001) Impact of first-line vs second-line antibiotics for the treatment of acute uncomplicated sinusitis. Jama 286: 1849–1856. 11597286
17. Livermore D, Hawkey P, (2005) CTX-M: changing the face of ESBLs in the UK. Journal of Antimicrobial Chemotherapy 56: 451–454. 16006451
18. Rupp ME, Fey PD, (2003) Extended spectrum β‐lactamase (ESBL)-producing Enterobacteriaceae. Drugs 63: 353–365. 12558458
19. Ramphal R, Ambrose PG, (2006) Extended-spectrum β‐lactamases and clinical outcomes: current data. Clinical infectious diseases 42: S164–S172. 16544267
20. Kang C-I, Chung DR, Ko KS, Peck KR, Song J-H, (2012) Risk factors for infection and treatment outcome of extended-spectrum β‐lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Annals of hematology 91: 115–121. doi: 10.1007/s00277-011-1247-7 21556875
21. Maiques E, Úbeda C, Campoy S, Salvador N, Lasa Í, et al. (2006) β‐Lactam antibiotics induce the SOS response and horizontal transfer of virulence factors in Staphylococcus aureus. Journal of bacteriology 188: 2726–2729. 16547063
22. Paterson DL, Ko W-C, Von Gottberg A, Casellas JM, Mulazimoglu L, et al. (2001) Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β‐lactamases: implications for the clinical microbiology laboratory. Journal of clinical microbiology 39: 2206–2212. 11376058
23. Livermore DM, Andrews JM, Hawkey PM, Ho P-L, Keness Y, et al. (2012) Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? Journal of antimicrobial chemotherapy 67: 1569–1577. doi: 10.1093/jac/dks088 22461311
24. Queenan AM, Foleno B, Gownley C, Wira E, Bush K, (2004) Effects of inoculum and β‐lactamase activity in AmpC-and extended-spectrum β‐lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. Journal of clinical microbiology 42: 269–275. 14715764
25. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, et al. (2013) Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam. Clinical infectious diseases 56: 1301–1309. doi: 10.1093/cid/cit017 23334813
26. Bedenić B, Beader N, Žagar Ž, (2001) Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended‐spectrum β‐lactamases. Clinical microbiology and infection 7: 626–635. 11737087
27. Brook I, (1989) Inoculum effect. Review of Infectious Diseases 11: 361–368.
28. Tan C, Phillip Smith R, Srimani JK, Riccione KA, Prasada S, et al. (2012) The inoculum effect and band‐pass bacterial response to periodic antibiotic treatment. Molecular systems biology 8.
29. Bush K, (1996) Is it important to identify extended-spectrum beta-lactamase-producing isolates? European Journal of Clinical Microbiology & Infectious Diseases 15: 361–364.
30. Meredith HR, Srimani JK, Lee AJ, Lopatkin AJ, You L, (2015) Collective antibiotic tolerance: mechanisms, dynamics and intervention. Nature chemical biology 11: 182–188. doi: 10.1038/nchembio.1754 25689336
31. Falagas M, Karageorgopoulos D, (2009) Extended-spectrum β‐lactamase-producing organisms. Journal of Hospital infection 73: 345–354. doi: 10.1016/j.jhin.2009.02.021 19596491
32. Conte JE, (2002) Manual of antibiotics and infectious diseases: treatment and prevention: Lippincott Williams & Wilkins.
33. Owens RC, Ambrose PG, (2005) Antimicrobial safety: focus on fluoroquinolones. Clinical infectious diseases 41: S144–S157. 15942881
34. Stahlmann R, Lode HM, (2013) Risks associated with the therapeutic use of fluoroquinolones. Expert opinion on drug safety 12: 497–505. doi: 10.1517/14740338.2013.796362 23651367
35. Leibovici L, Shraga I, Andreassen S, (1999) How do you choose antibiotic treatment? BMJ: British Medical Journal 318: 1614. 10364128
36. Cunha BA, (2001) Antibiotic side effects. Medical Clinics of North America 85: 149–185. 11190350
37. Mandell G, Dolin R, Bennett J, (2010) Mandell, Douglas, and Bennett's principles and practice of infectious diseases: Elsevier.
38. Thomson KS, Moland ES, (2001) Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β‐lactamase-producing Enterobacteriaceae. Antimicrobial agents and chemotherapy 45: 3548–3554. 11709338
39. Jacoby G, (1994) Genetics of extended-spectrum beta-lactamases. European Journal of Clinical Microbiology and Infectious Diseases 13: S2–S11. 7821301
40. Tanouchi Y, Pai A, Buchler NE, You L, (2012) Programming stress-induced altruistic death in engineered bacteria. Molecular systems biology 8.
41. Craig WA, (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical infectious diseases: 1–10. 9675442
42. Craig WA, (1995) Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagnostic microbiology and infectious disease 22: 89–96. 7587056
43. Burgess DS, Hastings RW, Hardin TC, (2000) Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clinical therapeutics 22: 66–75. 10688391
44. Reese AM, Frei CR, Burgess DS, (2005) Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum β‐lactamase-producing organisms. International journal of antimicrobial agents 26: 114–119. 16029947
45. Lodise TP, Lomaestro BM, Drusano GL, (2006) Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β‐lactam antibiotics. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 26: 1320–1332.
46. Ebert SC, Craig WA, (1990) Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infection Control and Hospital Epidemiology 11: 319–326. 2165081
47. Bhat SV, Peleg AY, Lodise TP, Shutt KA, Capitano B, et al. (2007) Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrobial agents and chemotherapy 51: 4390–4395. 17938179
48. Bush K, (1988) Beta-lactamase inhibitors from laboratory to clinic. Clinical microbiology reviews 1: 109–123. 3060240
49. Rossolini GM, Walsh T, Amicosante G, (1996) The Aeromonas metallo‐β‐lactamases: genetics, enzymology, and contribution to drug resistance. Microbial drug resistance 2: 245–252. 9158767
50. Livermore DM, (1995) beta-Lactamases in laboratory and clinical resistance. Clinical Microbiology Reviews 8: 557–584. 8665470
51. Livermore D, (1987) Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods. European Journal of Clinical Microbiology & Infectious Diseases 6: 439–445.
52. Minami S, Yotsuji A, Inoue M, Mitsuhashi S, (1980) Induction of beta-lactamase by various beta-lactam antibiotics in Enterobacter cloacae. Antimicrobial Agents and Chemotherapy 18: 382–385. 6968541
53. Hanson N, Sanders C, (1999) Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae. Current pharmaceutical design 5: 881–894. 10539994
54. Vu H, Nikaido H, (1985) Role of beta-lactam hydrolysis in the mechanism of resistance of a beta-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum beta-lactams. Antimicrobial agents and chemotherapy 27: 393–398. 3873215
55. Shah A, Hasan F, Ahmed S, Hameed A, (2004) Extended-spectrum β‐lactamases (ESBLs): characterization, epidemiology and detection. Critical reviews in microbiology 30: 25–32. 15116761
56. Levin BR, Udekwu KI, (2010) Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments. Antimicrobial agents and chemotherapy 54: 3414–3426. doi: 10.1128/AAC.00381-10 20516272
57. Bradford PA, (2001) Extended-spectrum β‐lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clinical microbiology reviews 14: 933–951. 11585791
58. Andrews JM, (2001) Determination of minimum inhibitory concentrations. Journal of antimicrobial Chemotherapy 48: 5–16. 11420333
59. Czock D, Keller F, (2007) Mechanism-based pharmacokinetic—pharmacodynamic modeling of antimicrobial drug effects. Journal of pharmacokinetics and pharmacodynamics 34: 727–751. 17906920
60. Jernberg C, Löfmark S, Edlund C, Jansson JK, (2010) Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 156: 3216–3223. doi: 10.1099/mic.0.040618-0 20705661
61. Labro M-T, (2000) Interference of antibacterial agents with phagocyte functions: immunomodulation or “immuno-fairy tales”? Clinical microbiology reviews 13: 615–650. 11023961
62. Lodise TP, Lomaestro B, Graves J, Drusano G, (2008) Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrobial agents and chemotherapy 52: 1330–1336. doi: 10.1128/AAC.01602-07 18227177
63. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, et al. (2011) Profound alterations of intestinal microbiota following a single dose of Clindamycin results in sustained susceptibility to C. difficile-induced colitis. Infection and Immunity: IAI. 05496–05411v05491.
64. Craig W, (1998) Choosing an antibiotic on the basis of pharmacodynamics. Ear, nose, & throat journal 77: 7–11; discussion 11–12.
65. Craig WA, (2001) Does the dose matter? Clinical infectious diseases 33: S233–S237. 11524724
66. Nevozhay D, Adams RM, Van Itallie E, Bennett MR, Balázsi G, (2012) Mapping the environmental fitness landscape of a synthetic gene circuit. PLoS computational biology 8: e1002480. doi: 10.1371/journal.pcbi.1002480 22511863
67. Charlebois DA, Balázsi G, Kærn M, (2014) Coherent feedforward transcriptional regulatory motifs enhance drug resistance. Physical Review E 89: 052708. 25353830
68. Tuomanen E, Durack D, Tomasz A, (1986) Antibiotic tolerance among clinical isolates of bacteria. Antimicrobial agents and chemotherapy 30: 521. 3539006
69. Lewis K, (2010) Persister cells. Annual review of microbiology 64: 357–372. doi: 10.1146/annurev.micro.112408.134306 20528688
70. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S, (2004) Bacterial persistence as a phenotypic switch. Science 305: 1622–1625. 15308767
71. Lewis K, (2006) Persister cells, dormancy and infectious disease. Nature Reviews Microbiology 5: 48–56. 17143318
72. Johnson PJ, Levin BR, (2013) Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus. PLoS genetics 9: e1003123. doi: 10.1371/journal.pgen.1003123 23300474
73. Levin BR, Rozen DE, (2006) Non-inherited antibiotic resistance. Nature Reviews Microbiology 4: 556–562. 16778840
74. Jõers A, Kaldalu N, Tenson T, (2010) The frequency of persisters in Escherichia coli reflects the kinetics of awakening from dormancy. Journal of bacteriology 192: 3379–3384. doi: 10.1128/JB.00056-10 20435730
75. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM, (2006) Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. American journal of respiratory and critical care medicine 174: 1153–1158. 16908866
76. Jia C, Qian M, Kang Y, Jiang D, (2014) Modeling stochastic phenotype switching and bet-hedging in bacteria: stochastic nonlinear dynamics and critical state identification. Quantitative Biology 2: 110–125.
77. Kussell E, Leibler S, (2005) Phenotypic diversity, population growth, and information in fluctuating environments. Science 309: 2075–2078. 16123265
78. Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS, (2012) The Sanford Guide to Antimicrobial Therapy 2012. Sperryville, VA: Antimicrobial Therpy, Inc.
79. Performance standards for antimicrobial susceptibility testing. Twenty-Second informational supplement NCCLS document M100-S22 National Committee for Clinical Laboratory Standards. Wayne, PA: Clinical and Laboratory Standards Institute. pp. 1–188.
80. Willing BP, Russell SL, Finlay BB, (2011) Shifting the balance: antibiotic effects on host—microbiota mutualism. Nature Reviews Microbiology 9: 233–243. doi: 10.1038/nrmicro2536 21358670
81. Yurtsev EA, Chao HX, Datta MS, Artemova T, Gore J, (2013) Bacterial cheating drives the population dynamics of cooperative antibiotic resistance plasmids. Molecular systems biology 9.
82. Tan C, Smith RP, Tsai M-C, Schwartz R, You L, (2014) Phenotypic Signatures Arising from Unbalanced Bacterial Growth. PLoS computational biology 10: e1003751. doi: 10.1371/journal.pcbi.1003751 25101949
83. Freeman JT, Sexton DJ, Anderson DJ, (2009) Emergence of extended-spectrum β‐lactamase-producing Escherichia coli in community hospitals throughout North Carolina: a harbinger of a wider problem in the United States? Clinical Infectious Diseases 49: e30–e32. doi: 10.1086/600046 19522654
84. Coque T, Baquero F, Canton R, (2008) Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 13: 5437–5453.
85. Villegas M, Kattan J, Quinteros M, Casellas J, (2008) Prevalence of extended‐spectrum β‐lactamases in South America. Clinical Microbiology and Infection 14: 154–158. 18154539